Editorial & Opinion
Diagnostic interpretation of CFH expression in pan-cancer analyses: the importance of factor H-like 1 isoform resolution.
| Τίτλος: | Diagnostic interpretation of CFH expression in pan-cancer analyses: the importance of factor H-like 1 isoform resolution. |
|---|---|
| Συγγραφείς: | Clark SJ; Department of Ophthalmology, Institute for Ophthalmic Research, Eberhard Karls University of Tübingen, Tübingen, Germany. simon.clark@uni-tuebingen.de.; University Eye Clinic, Eberhard Karls University of Tübingen, Tübingen, Germany. simon.clark@uni-tuebingen.de.; Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester, UK. simon.clark@uni-tuebingen.de. |
| Πηγή: | BMC cancer [BMC Cancer] 2026 Oct 11; Vol. 26 (1). Date of Electronic Publication: 2026 Oct 11. |
| Τύπος έκδοσης: | Letter |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: London : BioMed Central, [2001- |
| Ιατρικοί όροι (MeSH): | Complement Factor H*/genetics , Complement Factor H*/metabolism , Neoplasms*/diagnosis , Neoplasms*/genetics , Neoplasms*/metabolism , Biomarkers, Tumor*/genetics , Biomarkers, Tumor*/metabolism, Protein Isoforms/genetics ; Protein Isoforms/metabolism ; Humans ; Gene Expression Regulation, Neoplastic |
| Περίληψη: | Recent pan-cancer analyses have identified Complement Factor H (CFH) expression as an immune-related and prognostic biomarker. However, interpretation of CFH transcriptional data requires consideration of isoform specificity. The CFH gene encodes both full-length factor H (FH) and the biologically active splice isoform factor H-like 1 (FHL-1), which differ in structure and tissue localization. Common transcriptional and knockdown approaches do not distinguish between these isoforms, potentially introducing biological heterogeneity into diagnostic and prognostic assessments. Isoform-resolved analyses may therefore enhance the specificity and clinical utility of CFH-based biomarkers in oncology. (© 2026. The Author(s).) |
| Competing Interests: | Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests. |
| References: | Clin Cancer Res. 2021 Dec 1;27(23):6514-6528. (PMID: 34479957) Immunol Rev. 2023 Jan;313(1):25-45. (PMID: 36382387) Cancer Res. 2004 Sep 1;64(17):6310-8. (PMID: 15342420) Front Immunol. 2024 Feb 12;15:1135490. (PMID: 38410512) J Immunol. 2014 Nov 15;193(10):4962-70. (PMID: 25305316) BMC Cancer. 2025 Dec 26;26(1):142. (PMID: 41454282) Int J Oncol. 2011 Jul;39(1):161-8. (PMID: 21503575) Semin Immunopathol. 2018 Jan;40(1):65-74. (PMID: 28948331) |
| Substance Nomenclature: | 80295-65-4 (Complement Factor H) 0 (Protein Isoforms) 0 (Biomarkers, Tumor) 0 (CFH protein, human) |
| Entry Date(s): | Date Created: 20261010 Date Completed: 20261010 Latest Revision: 20261015 |
| Update Code: | 20261015 |
| PubMed Central ID: | PMC13654215 |
| DOI: | 10.1186/s12885-026-17134-4 |
| PMID: | 42859169 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1471-2407 |
|---|---|
| DOI: | 10.1186/s12885-026-17134-4 |